Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
Clinical trial NCT07480681 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07480681
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2028-03-01
- Enrollment
- 138
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.